Document is current

Article History

Accepted: 6 May 2025

First Online: 4 June 2025

Declarations

:

: No funding was received for the work undertaken for this manuscript.

: Diego Garcia-Borreguero has performed consulting work for Emalex Biosciences, Synendos Therapeutics and PsychoGenics Inc. David Anguizola has nothing to declare. Catalina Carballo has nothing to declare. Alba Garcia Aragón has nothing to declare. Alejandro Lopez reports no disclosures relevant to the manuscript. Brian Moncada has nothing to declare. Sergi Ferré’s work is supported by the intramural funds of the National Institute on Drug Abuse.

: Not applicable.

: Not applicable for the present study as this study does not involve new patients.

: Not applicable.

: The data generated during the course of this study are available upon reasonable request. The study protocol can be viewed by contacting the corresponding author.

: Not applicable.

: D.G.B. and S.F. conceived and designed the analysis; D.G.B., D.A., C.C., A.L., A.G.L., B.M. and S.F. collected and analysed the data. Statistical analysis was completed by D.G.B. All authors contributed to the analysis of data and the writing of the paper, approved the current manuscript and accepted its submission to CNS Drugs. All authors have read and approve the final submitted manuscript and agree to be accountable for the work.